$0.02
(Market cap
$3 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-2.2
-
Face value
--
-
Shares outstanding
1,626,867
10 Years Aggregate
CFO
$-99.91 Mln
EBITDA
$-132.61 Mln
Net Profit
$-116.73 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Purple Biotech (PPBT)
| -74.1 | 24.1 | -43.1 | -91.5 | -80.8 | -71.8 | -44.3 |
|
BSE Sensex
| -9.1 | -1.2 | 2.9 | -3.6 | 5.7 | 6.2 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Purple Biotech (PPBT)
| -86.0 | -69.6 | -43.5 | -64.5 | 2.1 | 388.7 | 18.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Purple Biotech (PPBT)
|
1.7 | 2.7 | 0.0 | -24.5 | -- | -221.9 | -- | 0.2 |
| 3.4 | 342.4 | 56.6 | -65.4 | -131.8 | -111.7 | -- | 8.6 | |
| 13.8 | 850.9 | 0.0 | -175.9 | -- | -106.8 | -- | 5.7 | |
| 12.1 | 2,151.8 | 549.1 | 17.9 | -6.3 | 1.4 | 123.8 | 1.7 | |
| 16.8 | 2,261.9 | 120.3 | -57.5 | -108.2 | -9.9 | -- | 4.1 | |
| 11.5 | 828.1 | 366.5 | 9.3 | 8.3 | 3.4 | 83.6 | 3.1 | |
| 3.6 | 654.8 | 4.1 | -187.9 | -4,613.1 | -233.9 | -- | 0.3 | |
| 13.5 | 834.1 | 0.6 | -60.0 | -9,892.6 | -119 | -- | 21.8 | |
| 6.3 | 609.7 | 143.5 | -158.2 | -80.2 | -168.9 | -- | 6.6 | |
| 25.5 | 2,927.9 | 449.6 | -188.2 | -41.1 | -28.5 | -- | 5.0 |
Shareholding Pattern
View DetailsAbout Purple Biotech (PPBT)
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that... blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and CAPTN-3 - IM1240 and IM1305, multi-valent antibody designed to activate anti-tumoral immune response against TAA positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company was incorporated in 1968 and is headquartered in Rehovot, Israel. Read more
-
Chief Executive Officer
Mr. Gil Efron CPA, M.A.
-
Head of Clinical & Regulatory Affairs
Dr. Michael Schickler Ph.D.
-
Headquarters
Rehovot
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Purple Biotech (PPBT)
What is the current share price of Purple Biotech (PPBT) Today?
The share price of Purple Biotech (PPBT) is $1.70 (NASDAQ) as of 31-Aug-2026 16:00 EDT. Purple Biotech (PPBT) has given a return of -80.8% in the last 3 years.
What is the current PB & PE ratio of Purple Biotech (PPBT)?
Since, TTM earnings of Purple Biotech (PPBT) is negative, P/E ratio is not available.
The P/B ratio of Purple Biotech (PPBT) is 0.22 times as on 28-Aug-2026, a 96 discount to its peers’ median range of 4.96 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.30 |
0.81 |
2024 |
-0.13 |
0.03 |
2023 |
-0.01 |
0.00 |
2022 |
-0.01 |
0.00 |
2021 |
0.00 |
0.00 |
What is the 52 Week High and Low of Purple Biotech (PPBT)?
The 52-week high and low of Purple Biotech (PPBT) are Rs 48.00 and Rs 1.16 as of 01-Sep-2026.
What is the market cap of Purple Biotech (PPBT)?
Purple Biotech (PPBT) has a market capitalisation of $ 3 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Purple Biotech (PPBT)?
Before investing in Purple Biotech (PPBT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.